FK 506 ameliorates the hepatic injury associated with ischemia.
Ischemic damage of the allograft liver is a major problem in clinical liver transplantation. Therefore the identification of hepatoprotective agents is a high priority at most liver transplantation programs. FK 506, a potent new immunosuppressive agent has been reported to possess hepatotrophic activity. To evaluate the putative hepatotrophic activity of FK 506 on experimental hepatic ischemia, rats were subjected to a subtotal hepatectomy following experimental ischemia and subsequent rat survival was assessed. FK 506 (0.3 mg/Kg) administered intravenously 24 hours prior to the induction of hepatic ischemia, reduced the subsequent mortality rate from 100% among controls given saline to only 20% (P less than 0.001). This observation demonstrates that FK 506 enhances the regenerative response of the liver to ischemic injury and may, in addition to its immunologic activity have hepatotrophic activity as well.
Department of Surgery, University of Pittsburgh, PA 15261.
M F
MF
Sakr
T I
TI
Hassanein
G M
GM
Zetti
D H
DH
Van Thiel
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006498:Hepatectomy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D066298:In Vitro Techniques; D007511:Ischemia / Q000188:drug therapy* / Q000401:mortality; D008099:Liver / Q000098:blood supply / Q000187:drug effects*; D008297:Male; D011292:Premedication; D051381:Rats; D011917:Rats, Inbred Lew; D015427:Reperfusion Injury / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate; D016559:Tacrolimus
D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D016559:Tacrolimus